Study identifier:D3250C00093
ClinicalTrials.gov identifier:NCT05384938
EudraCT identifier:N/A
CTIS identifier:N/A
A Postmarketing, Phase 4, Multicentre, Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma with Eosinophilic Phenotype in India.
In Adult Patients of Severe Asthma with Eosinophilic Phenotype in India
Phase 4
No
-
All
139
Interventional
18 Years - 75 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Jun 2024 by AstraZeneca
AstraZeneca
Not Applicable
No locations available
Arms | Assigned Interventions |
---|---|
Other: Benralizumab Single arm, Phase-IV | Biological/Vaccine: Benralizumab Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma with Eosinophilic Phenotype in India |